The Hopkins Lupus Cohort is an ongoing, prospective study in which SLE patients are followed by protocol, with visits at a minimum of every 3 months, now in its 16th year. The Cohort is racially balanced, with one-half of the members being African-American, and reflects a broad socioeconomic range. The Cohort represents a 15 year investment in the study of SLE outcomes, sponsored by NIH. It has led to a unique, prospective database of demographic, social, clinical and laboratory (routine, serologic, and antiphospholipid antibody) measures. The four major accomplishments of the Cohort during the last funding period were: 1) the determination that serologic markers of disease activity, such as anti-dsDNA, C3, and C4, have limited utility in the prediction of SLE flare; 2) the determination that the cumulative prednisone dose is predictive of coronary artery disease and osteoporosis, whereas high-dose prednisone is predictive of avascular necrosis; 3) the determination that antiphospholipid antibodies are associated with future risk of thrombosis and with atherosclerosis; and 4) the finding that the poor health status of SLE patients is associated with fibromyalgia, whereas fibromyalgia itself correlates highly with neurally-mediated hypotension, a form of autonomic neuropathy. In this revised grant, four new specific aims will be undertaken. First, in the cohort as a whole and in an inception cohort followed since diagnosis, we will determine the relative importance of disease activity versus corticosteroid treatment as a predictor of specific types of organ damage. Second, in a study of 75 patients seen monthly, we will investigate cytokines and platelet-related factors as predictors of disease activity. Third, 250 patients from the inception cohort will have carotid duplex and helical CT (for coronary calcification scores) at baseline and 2 years later to determine associates and predictors of atherosclerosis, including traditional and novel cardiovascular risk factors. Fourth, we will assess, in 100 SLE patients with and 100 without fibromyalgia, the frequency of autonomic neuropathy and the correlation with health status.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR043727-07
Application #
6769544
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Serrate-Sztein, Susana
Project Start
1996-09-30
Project End
2007-03-31
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
7
Fiscal Year
2004
Total Cost
$622,360
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Little, Jayne; Parker, Ben; Lunt, Mark et al. (2018) Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 57:677-687
Iftikhar, Mustafa; Kaur, Ramandeep; Nefalar, April et al. (2018) MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. Retina :
Merrill, Joan T; Petri, Michelle A; Buyon, Jill et al. (2018) Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 5:e000263
Eudy, Amanda M; Siega-Riz, Anna Maria; Engel, Stephanie M et al. (2018) Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis 77:855-860
Davidson, Julie E; Fu, Qinggong; Ji, Beulah et al. (2018) Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. J Rheumatol 45:671-677
Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Petri, Michelle et al. (2018) Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. J Rheumatol 45:393-396
Costedoat-Chalumeau, Nathalie; Houssiau, Frédéric; Izmirly, Peter et al. (2018) A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther 103:1074-1082
Giannakou, Ioanna; Chatzidionysiou, Katerina; Magder, Laurence S et al. (2018) Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Sci Med 5:e000287
Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :
Putterman, Chaim; Pisetsky, David S; Petri, Michelle et al. (2018) The SLE-key test serological signature: new insights into the course of lupus. Rheumatology (Oxford) 57:1632-1640

Showing the most recent 10 out of 220 publications